195 related articles for article (PubMed ID: 33509203)
1. Chromatin conformation changes in peripheral blood can detect prostate cancer and stratify disease risk groups.
Alshaker H; Mills R; Hunter E; Salter M; Ramadass A; Skinner BM; Westra W; Green J; Akoulitchev A; Winkler M; Pchejetski D
J Transl Med; 2021 Jan; 19(1):46. PubMed ID: 33509203
[TBL] [Abstract][Full Text] [Related]
2. Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection.
Pchejetski D; Hunter E; Dezfouli M; Salter M; Powell R; Green J; Naithani T; Koutsothanasi C; Alshaker H; Jaipuria J; Connor MJ; Eldred-Evans D; Fiorentino F; Ahmed H; Akoulitchev A; Winkler M
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765779
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer: Early Detection and Assessing Clinical Risk Using Deep Machine Learning of High Dimensional Peripheral Blood Flow Cytometric Phenotyping Data.
Cosma G; McArdle SE; Foulds GA; Hood SP; Reeder S; Johnson C; Khan MA; Pockley AG
Front Immunol; 2021; 12():786828. PubMed ID: 34975879
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation signatures of Prostate Cancer in peripheral T-cells.
Mehdi A; Cheishvili D; Arakelian A; Bismar TA; Szyf M; Rabbani SA
BMC Cancer; 2020 Jun; 20(1):588. PubMed ID: 32576165
[TBL] [Abstract][Full Text] [Related]
7. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
9. Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
Alinezhad S; Väänänen RM; Tallgrén T; Perez IM; Jambor I; Aronen H; Kähkönen E; Ettala O; Syvänen K; Nees M; Kallajoki M; Taimen P; Boström PJ; Pettersson K
Urol Oncol; 2016 Jun; 34(6):255.e15-22. PubMed ID: 26857646
[TBL] [Abstract][Full Text] [Related]
10. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
11. Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study.
Guan Y; Wang X; Guan K; Wang D; Bi X; Xiao Z; Xiao Z; Shan X; Hu L; Ma J; Li C; Zhang Y; Shou J; Wang B; Qian Z; Xing N
BMC Med Genomics; 2022 May; 15(Suppl 2):104. PubMed ID: 35513884
[TBL] [Abstract][Full Text] [Related]
12. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
15. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
16. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M
Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176
[TBL] [Abstract][Full Text] [Related]
17. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer.
Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS
Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
20. The role of genetic markers in the management of prostate cancer.
Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
